跳至主要内容
临床试验/NCT07744620
NCT07744620尚未招募不适用

Efficacy of Treatments for Overactive Bladder Based on Pathophysiological Phenotypes: A Comparison of Verbal Education, Biofeedback-Assisted Pelvic Floor Muscle Training, and Combined Tibial Nerve Stimulation

Far Eastern Memorial Hospital1 个研究点 分布在 1 个国家目标入组 201 人开始时间: 2026年8月3日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
201
试验地点
1
主要终点
Change in Overactive Bladder Symptom Score (OABSS)

研究概览

简要总结

The purpose of this clinical trial is to evaluate the effectiveness of different behavioral therapies and neuromodulation for treating women with idiopathic Overactive Bladder (OAB). The study aims to compare three 8-week treatment plans: oral education on Pelvic Floor Muscle Training (PFMT), biofeedback-assisted PFMT, and biofeedback-assisted PFMT combined with tibial nerve electrical stimulation using the "Enraf-Nonius" EMG-Biofeedback Unit. The main question it aims to answer is whether adding biofeedback and peripheral nerve stimulation provides better relief for OAB symptoms (such as urinary urgency, frequency, and nocturia) compared to standard oral education on PFMT alone. Participants will be randomly assigned to one of the three treatment groups and will track their daily pelvic floor exercises at home using a smartphone timer application. The study will also analyze whether patients with different OAB phenotypes (OAB-wet versus OAB-dry) respond differently to these treatment interventions.

详细描述

Overactive Bladder (OAB) is a syndrome characterized by urinary urgency, often accompanied by frequency and nocturia, with or without urgency urinary incontinence. Detrusor overactivity is considered the most common underlying cause. Pelvic Floor Muscle Training (PFMT) is a standard first-line behavioral therapy that helps inhibit detrusor contractions by strengthening the pelvic floor.

This randomized controlled trial investigates the additive clinical value of biofeedback and neuromodulation on top of standard PFMT. Participants are stratified based on their clinical phenotype (OAB-wet or OAB-dry) and randomly assigned to one of three groups for an 8-week intervention period: Group 1 receives standard oral education on PFMT; Group 2 receives biofeedback-assisted PFMT to improve muscle contraction accuracy; and Group 3 receives biofeedback-assisted PFMT combined with percutaneous tibial nerve electrical stimulation. The neuromodulation intervention aims to inhibit involuntary detrusor contractions and regulate bladder nerve signals through peripheral nerve conduction.

All clinical interventions and assessments are conducted in a dedicated, private biofeedback treatment room. Participants are scheduled for in-person clinic visits at weeks 0, 2, 4, and 8. During these visits, participants in Groups 1 and 2 will undergo routine assessment and muscle contraction quality checks lasting 30 to 40 minutes. Participants in Group 3 will additionally receive a 30 to 40-minute session of tibial nerve electrical stimulation (parameters: 20 Hz, 200 μs, with intensity adjusted to the maximum tolerable painless threshold).

In addition to clinic visits, all participants are required to perform daily home-based PFMT. They will track their exercise frequency and compliance using a dedicated smartphone timer application. The study seeks to provide evidence for personalized clinical treatment decisions by analyzing which level of intervention yields the best symptom relief and quality of life improvement for different OAB phenotypes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Stable on chronic medications: Participants must have been on a long-term, regular regimen of routine medications for chronic conditions (e.g., hypertension, diabetes, hyperlipidemia) prior to study entry, with no expected changes in dosage or administration during the 8-week study period.
  • Diagnosed with Overactive Bladder (OAB) according to the International Continence Society (ICS) definition, including urgency, frequency, and nocturia, with or without urgency urinary incontinence (must be documented as OAB-wet or OAB-dry).
  • Symptoms persisting for at least 3 months.
  • Overactive Bladder Symptom Score (OABSS) total score ≥ 3 at baseline (Week 0), with an urgency score (Question 3) ≥ 2 (meeting the clinical threshold for core OAB symptom intensity).

排除标准

  • Concurrent active urinary tract infection (UTI), bladder stones, or urinary tract malignancy.
  • Inability to follow instructions for muscle training due to cognitive impairment or severe psychiatric illness.
  • Presence of implanted electronic medical devices (e.g., cardiac pacemakers) (contraindication for electrical stimulation).
  • Currently pregnant women or those planning to become pregnant during the study period.
  • Use of antimuscarinics (e.g., Oxybutynin, Tolterodine, Solifenacin) or beta-3 adrenergic receptor agonists (e.g., Mirabegron) within 2 weeks prior to study entry.
  • Receipt of pelvic or perineal physical therapy outside of this study protocol (e.g., vaginal or anal probe electrical stimulation, pelvic floor magnetic stimulation, transcutaneous microcurrent stimulation) within 2 weeks prior to study entry.
  • Receipt of intravesical Botulinum toxin (Botox) injections, sacral neuromodulation, or any surgical treatment related to urinary incontinence or pelvic organ prolapse within 2 weeks prior to study entry.

结局指标

主要结局

Change in Overactive Bladder Symptom Score (OABSS)

时间窗: Baseline (Week 0), Week 2, Week 4, and Week 8

he OABSS is a validated, self-administered questionnaire used as a core clinical scale to evaluate the severity of overactive bladder symptoms. It consists of four items: daytime frequency, nighttime frequency, urgency, and urgency incontinence. The total score is calculated by summing the scores of the four items, with a higher total score indicating more severe OAB symptoms. The primary endpoint will evaluate the change in the total score from baseline to the end of the 8-week intervention.

Change in 3-day Bladder Diary Parameters

时间窗: Baseline (Week 0) and Week 8

Participants will record their voiding habits over a 72-hour period, including fluid intake, number of micturitions (frequency), and number of urinary incontinence episodes.

次要结局

  • Change in Overactive Bladder Questionnaire (OAB-q) Score(Baseline (Week 0), Week 2, Week 4, and Week 8)
  • Change in King's Health Questionnaire (KHQ) Score(Baseline (Week 0), Week 2, Week 4, and Week 8)
  • Subjective Symptom Improvement Rating(Baseline (Week 0), Week 2, Week 4, and Week 8)
  • Change in Pelvic Floor Muscle Strength(Baseline (Week 0), Week 2, Week 4, and Week 8)
  • Change in PFMT Self-Efficacy and Home Exercise Compliance(Baseline (Week 0), Week 2, Week 4, and Week 8)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验